Paricalcitol

Description

Paricalcitol · CAS 131918-61-1 · C27H44O3. UNII 6702D36OG5. Solubility: 6.80e-03 g/L; LogP: 4.5.

Identification

CAS Registry Number	131918-61-1
PubChem CID	5281104
Molecular formula	C27H44O3
IUPAC name	trans-(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
UNII (FDA)	6702D36OG5

Computed Descriptors

Molecular Weight	416.6
XLogP3	5
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	5
Exact Mass	416.32904526
Monoisotopic Mass	416.32904526
Topological Polar Surface Area	60.7
Heavy Atom Count	30
Formal Charge	0

Physical & Chemical Properties

Solubility	6.80e-03 g/L
LogP	4.5

Physical description & handling notes

• Solid
• White, crystalline powder
• Parenteral: Injection, for IV use only: 5 ug/mL, Zemplar (with alcohol 20% v/v and propylene glycol 30% v/v), (Abbott).

GHS Hazard Classification

Reported hazard statements	H300 (72.5%), H301, H311 (27.5%), H330 (27.5%), H351 (67.6%), H361 (71.8%), H362 (66.9%), H372 (27.5%)

Documented Uses

• Treatment of secondary hyperparathyroidism in patients with chronic kidney disease
• Consumption (g per capita) in the USA (2002): 2.84e-08
• H. F. DeLuca et al., EP patent 387077; eidem, US patent 5587497 (1990, 1996 both to Wisconsin Alum. Res.).
• For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
• Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4. /Included in US product labeling/
• /Paricalcitol/ should not be given to patients with evidence of vitamin D toxicity, hypercalcemia, or hypersensitivity to any ingredient in this product.

Synonyms

Paricalcitol; 131918-61-1; Zemplar; Compound 49510; 19-Nor-1alpha,25-dihydroxyvitamin D2; Compound-49510; 19-Nor-1,25-(OH)2D2; DTXSID4048640; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 6702D36OG5; CHEBI:7931; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; DTXCID7028566; paricalcitolum; (1R,3R,7E)-17beta-((2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-9,10-secoestra-5,7-diene-1,3-diol; RefChem:56862

Frequently Asked Questions

What are the CAS number and molecular formula of Paricalcitol?

CAS 131918-61-1; molecular formula C27H44O3; molecular weight — g/mol.

What other names is Paricalcitol known by?

Paricalcitol, 131918-61-1, Zemplar, Compound 49510, 19-Nor-1alpha,25-dihydroxyvitamin D2, Compound-49510.

Is Paricalcitol classified as hazardous?

Hazard statements reported: H300, H301, H311, H330, H351.

What are the key physical properties of Paricalcitol?

Solubility: 6.80e-03 g/L; LogP: 4.5.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.